FI973039A0 - Uusia farnesyylitransferaasin inhibiittoreita, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksia - Google Patents
Uusia farnesyylitransferaasin inhibiittoreita, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksiaInfo
- Publication number
- FI973039A0 FI973039A0 FI973039A FI973039A FI973039A0 FI 973039 A0 FI973039 A0 FI 973039A0 FI 973039 A FI973039 A FI 973039A FI 973039 A FI973039 A FI 973039A FI 973039 A0 FI973039 A0 FI 973039A0
- Authority
- FI
- Finland
- Prior art keywords
- farnecyltransferase
- inhibitors
- preparation
- new
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
- C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9500494A FR2729390A1 (fr) | 1995-01-18 | 1995-01-18 | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
| PCT/FR1996/000067 WO1996022278A1 (fr) | 1995-01-18 | 1996-01-16 | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FI973039A FI973039A (fi) | 1997-07-17 |
| FI973039A0 true FI973039A0 (fi) | 1997-07-17 |
Family
ID=9475215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI973039A FI973039A0 (fi) | 1995-01-18 | 1997-07-17 | Uusia farnesyylitransferaasin inhibiittoreita, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksia |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5750567A (fr) |
| EP (1) | EP0804415A1 (fr) |
| JP (1) | JPH10512560A (fr) |
| KR (1) | KR19980701469A (fr) |
| CN (1) | CN1169145A (fr) |
| AU (1) | AU4543696A (fr) |
| BR (1) | BR9606970A (fr) |
| CA (1) | CA2211786A1 (fr) |
| CZ (1) | CZ228297A3 (fr) |
| FI (1) | FI973039A0 (fr) |
| FR (1) | FR2729390A1 (fr) |
| NO (1) | NO973222D0 (fr) |
| PL (1) | PL321380A1 (fr) |
| SK (1) | SK95997A3 (fr) |
| TR (1) | TR199700660T1 (fr) |
| WO (1) | WO1996022278A1 (fr) |
| ZA (1) | ZA96258B (fr) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1094815E (pt) * | 1998-07-06 | 2004-04-30 | Janssen Pharmaceutica Nv | Inibidores da proteina farnesil transferase para tratamento de artropatias |
| CA2360039C (fr) * | 1999-01-22 | 2009-11-24 | Emory University | Mutations du vih-1 obtenues au moyen de b-2',3'-didehydro-2',3'-didesoxy-5-fluorocytidine |
| FR2796946A1 (fr) * | 1999-07-30 | 2001-02-02 | Aventis Pharma Sa | Nouveaux derives 8-carbonyl chromanes, leur preparation et leur utilisation en therapeutique |
| FR2796943A1 (fr) * | 1999-07-30 | 2001-02-02 | Aventis Pharma Sa | Derives de benzoxazinnes, leur procede de preparation et leur utilisation en therapeutique |
| ATE550019T1 (de) | 2005-05-17 | 2012-04-15 | Merck Sharp & Dohme | Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US7553854B2 (en) | 2006-04-19 | 2009-06-30 | Novartis Vaccines And Diagnostics, Inc. | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling |
| EP2946778A1 (fr) | 2006-09-22 | 2015-11-25 | Merck Sharp & Dohme Corp. | Procédé de traitement utilisant des inhibiteurs de la synthèse d'acides gras |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| EA016079B1 (ru) | 2007-01-10 | 2012-01-30 | Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа | Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp) |
| BRPI0808523A2 (pt) | 2007-03-01 | 2014-08-19 | Novartis Vaccines & Diagnostic | Inibidores de pim cinase e métodos de seu uso |
| JP5378362B2 (ja) | 2007-05-21 | 2013-12-25 | ノバルティス アーゲー | Ｃｓｆ−１ｒ阻害剤、組成物および使用方法 |
| WO2009002495A1 (fr) | 2007-06-27 | 2008-12-31 | Merck & Co., Inc. | Dérivés de 4-carboxybenzylamino utilisés en tant qu'inhibiteurs de l'histone désacétylase |
| US7932036B1 (en) | 2008-03-12 | 2011-04-26 | Veridex, Llc | Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase |
| WO2010114780A1 (fr) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibiteurs de l'activité akt |
| JP6073677B2 (ja) | 2009-06-12 | 2017-02-01 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 縮合複素環式化合物およびそれらの使用 |
| BR112012008849A2 (pt) | 2009-10-14 | 2015-09-22 | Schering Corp | composto, composição farmacêutica, e, uso de um composto |
| EP2937345B1 (fr) | 2009-12-29 | 2018-03-21 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de la kinase raf de type ii |
| CN103080093A (zh) | 2010-03-16 | 2013-05-01 | 达纳－法伯癌症研究所公司 | 吲唑化合物及其应用 |
| EP2584903B1 (fr) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk |
| CN106244707A (zh) | 2010-07-28 | 2016-12-21 | 维里德克斯有限责任公司 | 急性髓细胞性白血病应答法尼基转移酶抑制剂治疗的测定方法 |
| EP3330377A1 (fr) | 2010-08-02 | 2018-06-06 | Sirna Therapeutics, Inc. | Inhibition à médiation par interférence arn de caténine (protéine associée à cadhérine), expression du gène bêta 1 (ctnnb1) à l'aide de petit acide nucléique interférent (sian) |
| US9029341B2 (en) | 2010-08-17 | 2015-05-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA) |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| WO2012030685A2 (fr) | 2010-09-01 | 2012-03-08 | Schering Corporation | Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk |
| EP2615916B1 (fr) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk |
| US9260471B2 (en) | 2010-10-29 | 2016-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
| US9351965B2 (en) | 2010-12-21 | 2016-05-31 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
| JP2014514321A (ja) | 2011-04-21 | 2014-06-19 | メルク・シャープ・アンド・ドーム・コーポレーション | インスリン様増殖因子１受容体阻害剤 |
| EP2770987B1 (fr) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Nouveaux composés qui sont des inhibiteurs d'erk |
| AU2012340200B2 (en) | 2011-11-17 | 2017-10-12 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-Terminal Kinase (JNK) |
| WO2013165816A2 (fr) | 2012-05-02 | 2013-11-07 | Merck Sharp & Dohme Corp. | Compositions de petit acide nucléique interférent (sina) |
| JP6280554B2 (ja) | 2012-09-28 | 2018-02-14 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｅｒｋ阻害剤である新規化合物 |
| WO2014063068A1 (fr) | 2012-10-18 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de cycline-dépendante kinase 7 (cdk7) |
| WO2014063054A1 (fr) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de kinase moelle osseuse sur chromosome x (bmx) et leurs utilisations |
| USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| AU2013352568B2 (en) | 2012-11-28 | 2019-09-19 | Merck Sharp & Dohme Llc | Compositions and methods for treating cancer |
| CN105073746B (zh) | 2012-12-20 | 2017-03-22 | 默沙东公司 | 作为hdm2抑制剂的取代的咪唑并吡啶 |
| EP2951180B1 (fr) | 2013-01-30 | 2018-05-02 | Merck Sharp & Dohme Corp. | Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2 |
| EP3041938A1 (fr) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Polynucléotides circulaires |
| CN105849099B (zh) | 2013-10-18 | 2020-01-17 | 达纳-法伯癌症研究所股份有限公司 | 周期蛋白依赖性激酶7(cdk7)的多环抑制剂 |
| US20160264551A1 (en) | 2013-10-18 | 2016-09-15 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
| US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
| US10017477B2 (en) | 2014-04-23 | 2018-07-10 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
| JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
| CA2972239A1 (fr) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de la kinase cycline-dependante 7 (cdk7) |
| CA2978518C (fr) | 2015-03-27 | 2023-11-21 | Nathanael S. Gray | Inhibiteurs de kinases cycline-dependantes |
| US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| NZ736853A (en) | 2015-08-17 | 2019-09-27 | Kura Oncology Inc | Methods of treating cancer patients with farnesyl transferase inhibitors |
| EP4019515A1 (fr) | 2015-09-09 | 2022-06-29 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de kinases cycline-dépendantes |
| JOP20190055A1 (ar) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
| WO2018085518A2 (fr) | 2016-11-03 | 2018-05-11 | Kura Oncology, Inc. | Méthodes de traitement de patients cancéreux par inhibiteurs de farnésyltransférase |
| CA3058134A1 (fr) | 2017-04-13 | 2018-10-18 | Aduro Biotech Holdings, Europe B.V. | Anticorps anti-sirp alpha |
| EP3706742B1 (fr) | 2017-11-08 | 2023-03-15 | Merck Sharp & Dohme LLC | Inhibiteurs de prmt5 |
| WO2019113269A1 (fr) | 2017-12-08 | 2019-06-13 | Kura Oncology, Inc. | Méthodes de traitement de patients cancéreux avec des inhibiteurs de la farnésyltransférase |
| WO2019148412A1 (fr) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anticorps bispécifiques anti-pd-1/lag3 |
| EP3833668A4 (fr) | 2018-08-07 | 2022-05-11 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
| WO2020033284A1 (fr) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
| US20220143006A1 (en) | 2019-03-15 | 2022-05-12 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5536750A (en) * | 1992-10-29 | 1996-07-16 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5504212A (en) * | 1992-10-29 | 1996-04-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5686472A (en) * | 1992-10-29 | 1997-11-11 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5523456A (en) * | 1994-09-29 | 1996-06-04 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
-
1995
- 1995-01-18 FR FR9500494A patent/FR2729390A1/fr active Granted
-
1996
- 1996-01-12 ZA ZA96258A patent/ZA96258B/xx unknown
- 1996-01-16 CN CN96191528A patent/CN1169145A/zh active Pending
- 1996-01-16 BR BR9606970A patent/BR9606970A/pt not_active Application Discontinuation
- 1996-01-16 KR KR1019970704859A patent/KR19980701469A/ko not_active Application Discontinuation
- 1996-01-16 SK SK959-97A patent/SK95997A3/sk unknown
- 1996-01-16 WO PCT/FR1996/000067 patent/WO1996022278A1/fr not_active Application Discontinuation
- 1996-01-16 CZ CZ972282A patent/CZ228297A3/cs unknown
- 1996-01-16 TR TR97/00660T patent/TR199700660T1/xx unknown
- 1996-01-16 PL PL96321380A patent/PL321380A1/xx unknown
- 1996-01-16 AU AU45436/96A patent/AU4543696A/en not_active Abandoned
- 1996-01-16 US US08/875,005 patent/US5750567A/en not_active Expired - Fee Related
- 1996-01-16 EP EP96901397A patent/EP0804415A1/fr not_active Ceased
- 1996-01-16 JP JP8522080A patent/JPH10512560A/ja active Pending
- 1996-01-16 CA CA002211786A patent/CA2211786A1/fr not_active Abandoned
-
1997
- 1997-07-10 NO NO973222A patent/NO973222D0/no unknown
- 1997-07-17 FI FI973039A patent/FI973039A0/fi unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL321380A1 (en) | 1997-12-08 |
| ZA96258B (en) | 1996-08-01 |
| FI973039A (fi) | 1997-07-17 |
| CA2211786A1 (fr) | 1996-07-25 |
| CZ228297A3 (en) | 1997-10-15 |
| SK95997A3 (en) | 1997-12-10 |
| CN1169145A (zh) | 1997-12-31 |
| JPH10512560A (ja) | 1998-12-02 |
| EP0804415A1 (fr) | 1997-11-05 |
| FR2729390B1 (fr) | 1997-02-21 |
| MX9705270A (es) | 1997-10-31 |
| KR19980701469A (ko) | 1998-05-15 |
| AU4543696A (en) | 1996-08-07 |
| NO973222L (no) | 1997-07-10 |
| WO1996022278A1 (fr) | 1996-07-25 |
| BR9606970A (pt) | 1997-11-04 |
| TR199700660T1 (xx) | 1998-01-21 |
| FR2729390A1 (fr) | 1996-07-19 |
| NO973222D0 (no) | 1997-07-10 |
| US5750567A (en) | 1998-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI973039A0 (fi) | Uusia farnesyylitransferaasin inhibiittoreita, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksia | |
| NO973922L (no) | Nye taxoider, deres fremstilling og farmasöytiske preparater inneholdende forbindelsene | |
| FI973279A (fi) | Uudet farnesyylitransferaasin inhibiittorit, niiden valmistus ja niitä sisältävät farmaseuttiset koostumukset | |
| CY2005007I1 (el) | Φαρμακευτικες συνθεσεις που περιεχουν δαριφενακινη | |
| IS4706A (is) | Lyfjasamsetningar | |
| EE9500064A (et) | Asendatud 1H-imidasoolid, nende valmistamismeetodid ja farmatseutilised kompositsioonid | |
| NO962606L (no) | Farmasöytisk sammensetning | |
| EE9800028A (et) | Iprotroopiumsoolad, neid sisaldavad ravimkompositsioonid ja nende kasutamine | |
| DE69634053D1 (de) | Oral anzuwendende Arzneizusammensetzung enthaltend 2-Methyl-thienobenzodiazepin | |
| DK0876362T3 (da) | Nye taxoider, deres fremstilling og farmaceutiske præparater deraf | |
| ID18663A (id) | Komposisi farmasi berlapis enterik | |
| ID18352A (id) | Komposisi-komposisi farmasi | |
| FI951789A (fi) | Uusia taksaanijohdannaisia, niiden valmistus ja niitä sisältävät farmaseuttiset koostumukset | |
| DK0820448T3 (da) | Nye taxoider, deres fremstilling og farmaceutiske præparater deraf | |
| EE9800264A (et) | Taksoidid, nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid | |
| DE69614407D1 (de) | Pharmazeutische zusammensetzungen | |
| EE9800400A (et) | Diklofenaaki sisaldavad farmatseutilised kompositsioonid | |
| FI973229A (fi) | Uusi farmaseuttinen koostumus | |
| LV11727A (lv) | Farmaceitiska kompozicija | |
| EE03996B1 (et) | Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine | |
| EE9900206A (et) | N-sulfonüülindoliiniderivaate sisaldavad farmatseutilised kompositsioonid | |
| FI964900A (fi) | Uudet taksoidit, niiden valmistus ja niitä sisältävät farmaseuttiset valmisteet | |
| PT941100E (pt) | Composicoes farmaceuticas | |
| FI973280A (fi) | Farmaseuttinen koostumus | |
| ITMI942166A0 (it) | Composizioni farmaceutiche miorilassanti |